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 tumours [version 1; referees: 2 approved, 1 approved with
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Abstract
Transcriptomic profiling of skin disease using next generation sequencing
allows for detailed information on aspects of RNA biology including gene
expression, non-coding regulatory elements and gene splicing. The application
of RNA sequencing to human skin disease and cancer is often hampered by
degraded RNA. Here we describe a protocol that allows for consistently intact
RNA to be extracted from snap frozen skin biopsy samples, which has been
validated in a clinical trial setting.
Human skin tumour punch biopsies (n=28) ranging from 4-6mm in diameter
were obtained from 14 patients with an inherited skin tumour syndrome (CYLD
cutaneous syndrome) and frozen in liquid nitrogen prior to being stored at
-80°C. These samples were then subject to cyrostat sectioning, allowing for
histological assessment, and were homogenised using a bead-based lysis
platform. RNA extraction was performed using a silica column-based system.
RNA concentration was measured using fluorescent quantitation and RNA
integrity assessed using microfluidic gel electrophoresis. We also processed
normal skin biopsies using the same protocol (n=10). The mean RNA integrity
score of the tumour and normal samples was 9.5, and the quantity of RNA
obtained from the small amounts of tissue used exceeded requirements for
RNA-seq library generation.
We propose that the method of RNA extraction suggested here allows for
transcriptomic profiling from small pieces of human tissue without the need for
PCR amplification during library preparation. This protocol could be utilised in
healthy and diseased skin to improve mechanistic understanding in a range of
human skin diseases.
Keywords
Skin biopsy, tumour, CYLD, RNA sequencing, cancer, clinical trial,
transcriptomics.
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Introduction
Skin has evolved as a protective barrier against environmental 
stresses such as physical damage, ultraviolet radiation exposure 
and pathogenic infections. It is a complex tissue, consisting 
of many cell types, including keratinocytes, immune cells, 
melanocytes, fibroblasts, adipocytes, nerve fibres, smooth 
muscle and endothelial cells (Cole et al., 2001). Skin diseases 
may involve any of these constituent cells, and transcriptomic 
profiling of diseased human skin can inform understanding of 
disease pathogenesis. The accessible nature of the skin, unlike 
tissues such as the brain or liver, and the low patient impact 
of skin biopsy, make the use of transcriptomics in human skin 
particularly attractive. Whole punch biopsies have been studied 
using transcriptome-wide approaches, giving insights into the 
inflammatory skin disease psoriasis (Zolotarenko et al., 2016).
Reliably obtaining high quality RNA of sufficient quantity 
from small samples typical of those derived from punch biop-
sies is, however, problematic. The reasons for this are diverse 
and include suboptimal tissue disruption and endogenous RNase 
activity, resulting in skin being a tissue that is amongst the most 
challenging to obtain intact RNA from (Walker et al., 2016) 
(Kaufmann et al., 1980). RNA is also a highly unstable 
molecule. Once extracted from cells or tissues it has a very short 
half-life and is easily degraded (Brooks, 1998; Tan & Yiap, 2009). 
RNA is chemically unstable due to the presence of a hydroxyl 
group at the 2’ and thus is highly susceptible to hydrolysis by 
ribonuclease enzymes. The hydrolysis or cleavage of RNA can 
also occur spontaneously, without the presence of a catalyst or 
enzyme (Elliott & Ladomery, 2011). Together, these challenges 
may discourage the inclusion of transcriptomics in clinical 
trials involving human skin, where such information may offer 
mechanistic insights.
Methods of RNA extraction from human skin have been evolv-
ing. Early approaches required large amounts of tissue, and were 
not amenable to medium/high throughput lysis, as each sample 
had to be disrupted in liquid nitrogen (Hipfel et al., 1998; 
Kaufmann et al., 1980). Whole punch biopsies of the skin have 
been successfully disrupted by low throughput devices, such as 
the Kinematica Polytron 1300D homogenizer and FastPrep120 
bead beater (Berglund et al., 2007). 4 mm skin biopsies have 
also been subjected to ammonium thiocyanate-induced dermo- 
epidermal separation and subsequently homogenized using 
bead-based lysis (Clemmensen et al., 2009); however the RNA 
integrity may have been suboptimal due to tissue processing. 
Importantly none of these approaches allow for histological 
assessment of the skin sample, which is relevant in interpreting 
sequencing results of diseased skin. Laser capture microdissection 
is an alternative method with histological information, with the 
limitations being cost of laser capture microscopy equipment, 
small amount of RNA obtained, and RINs that may be lower 
(circa 7.0) (Butler et al., 2016). An additional amplification 
stage is also often required when starting from small amounts of 
RNA during library generation, which may introduce an element 
of bias (Jackson et al., 2014).
Here we report an efficient method of RNA extraction from 
skin tumours obtained using punch biopsies under local anaes-
thetic in a clinical trial involving patients with an inherited 
skin tumour syndrome. We also validated this method in normal 
human skin biopsies. Downstream analysis demonstrated high 
yield and RNA integrity, allowing for transcriptomic profiling 
using RNA sequencing.
Methods
Ethics
Regulatory approvals for the present study were sought 
and obtained from an ethics review committee (National 
Research Ethics Service Committee North East-Tyne and Wear 
Ref:14/NE//080 and 06/1059) and the Medicines Health 
Regulatory authority (EudraCT: 2014-001342-21). Patients 
provided written, informed consent for biopsy and use of their 
tissue samples for research. This study used samples collected 
as part of a clinical trial, registered at ISCRTN 75715723. The 
study was performed in accordance with the Declaration of 
Helsinki.
Sample collection
Tumours scheduled for biopsy as part of the trial protocol were 
identified using tumour maps and photographs. Tumour identi-
fiers were labelled onto cryovials in advance of the procedure. 
Skin biopsies were performed under local anaesthetic, and one 
sample was taken at a time. The biopsy was transferred to a 
labelled cryovial, with identifiers checked together with a 
research nurse. The sample was then immediately immersed in 
liquid nitrogen. All samples were logged in accordance with 
standard operating procedures and stored in a -80°C freezer 
within a designated Human Tissue Authority freezer that is 
subject to temperature monitoring.
Sample processing
A full working protocol is detailed in Supplementary File 1, 
and the key steps are outlined here. Standard precautions to 
prevent contamination with RNAses were employed. The 
sample was removed from the freezer and transferred on dry ice 
to the cryostat. The sample identifier was used to label slides 
and preweighed lysis tubes, which were supplied prefilled 
with beads (Precellys). Skin punch biopsy samples of tumours 
(4–6 mm diameter) were mounted on a cork piece using 
cutting compound (OCT), and then serially sectioned (Figure 1). 
Each skin biopsy was cryosectioned at two levels and 
ten 30-micron curls were taken from each level for RNA 
extraction; two were taken from each biopsy. Sections were then 
taken for histology and applied to a standard slide, and subject 
to haematoxylin and eosin staining. Following cryosection-
ing, material was immediately placed into the bead lysis tube, 
weighed again and then cold lysis buffer (RLT) containing 
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Figure 1. A method for extracting high quality RNA from small skin biopsy samples which is suitable for RNA sequencing. (a) Diagram 
indicating key steps in the work flow, and the need to keep samples cold throughout. (A) Human skin punch biopsy (B) Freezing of sample 
within 30 seconds. (C–D) Cryostat sectioning of punch biopsy and curls obtained. (E–F) Addition of lysis buffer to single use bead tube, 
followed by homogenisation in the bead-based lysis machine where up to 24 samples can be processed at once. (G) Silica spin column 
based RNA extraction performed at 4 degrees. (b) Microfluidic gel analysis of total RNA demonstrates distinct 18S and 28S ribosomal bands, 
consistent with the high RNA integrity scores (c) demonstrated across samples. (d) FASTQc assessment of reads indicate high quality reads 
in libraries developed from this dataset.
beta-mecaptoethanol was added (Qiagen RNeasy Micro Kit No 
74004). The tube was frozen on dry ice and then returned to the 
-80°C freezer until RNA extraction was performed.
RNA extraction and quality control
The protocol supplied with the silica spin column kit (Qiagen 
RNeasy Micro Kit No 74004, Qiagen UK) was followed 
with modifications, as indicated in the working protocol 
(Supplementary File 1). Briefly, bead tubes were taken from the 
-80°C  freezer on dry ice. Tissue was then homogenized in a 
Precellys Evolution homogeniser (Bertin, France) for 20 seconds 
at 5500 bpm. After homogenization, the lysate was applied to the 
column, and then wash steps were performed. On-column DNase 
digestion was performed for 7 minutes at room temperature. 
Further washes were performed before RNA was eluted from 
the column with RNase-free water. All protocol steps were 
performed in a cold centrifuge at 4°C at 15000 rpm apart from the 
DNase incubation step stated above. Eluted RNA was measured 
using the Qubit BR assay kit (Thermofisher, UK). RNA quality 
was measured using a microfluidic gel electrophoresis chip 
(Bioanalyer RNA 6000 Nano Chip, Agilent UK). RNA integ-
rity numbers were obtained with the software provided (2100 
Expert Software: Revision B.02.09 (SR1)) with the Agilent 
2100 Bioanalyser (Agilent, UK) (Schroeder et al., 2006).
Transcriptomic analyses
To obtain the cytokeratin signatures of differentially expressed 
genes in cylindroma and spiradenoma compared to con-
trol skin, three tumour transcript files were compared to three 
control skin sample files. RNA from each sample was used 
to generate sequencing libraries using the Illumina Truseq 
stranded mRNA kit. Libraries were sequenced using an Illumina 
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Hiseq 2500, giving 45 million paired end reads per sample 
which were 100 bp in length. FASTQ files were checked for 
quality using FASTQc and aligned using the splice aware 
aligner program STAR (v. 2.5.2b) to generate alignment files 
(Dobin et al., 2013). The read counts for each sample file were 
obtained using the R package Subread (v.1.28.1) (Liao et al., 
2013). Differential gene expression analysis was carried out using 
DeSeq2 v.1.18.1 (Love et al., 2014). Cytokeratin genes that 
were differentially expressed with a false discovery rates of 
<0.05 after correction for multiple hypothesis testing are listed 
in Table 3.
Results
Consistent high-quality RNA is extracted from multiple skin 
tumours
28 skin biopsies were cryosectioned and material with an 
average weight of 10.4mg (range 5 –14 mg) was obtained at two 
levels in each biopsy Figure 1a. RNA was obtained from a total 
of 56 levels, with total yield exceeding the requirements for 
library preparation for RNA sequencing (yields typically >500ng) 
in the majority of samples. Sections taken for histology were 
stained using haematoxylin and eosin, and confirmed adja-
cent curls were taken from cylindroma and spiradenoma in 25 
out of 28 of biopsies; three biopsies demonstrated trichoepi-
thelioma. In 3 out of 56 levels, RNA was not obtained and this 
correlated with histology reflecting relatively acellular dermis 
beneath the level of the tumour. The range of concentrations 
and quality of RNA extracted from tumours are indicated 
in Table 1 and Figure 1b and c, indicating a mean RIN of 9.5 
(range 8.5–10). Control skin sample yields and integrity (mean 
RIN 9.5; range 8.8–10) are indicated in Table 2.
Table 1. RNA concentrations and integrity in the 28 skin 
tumour biopsies studied, with 2 samples taken per biopsy. 
Qualitative and quantitative measurements of the total RNA 
isolated from normal skin punch biopsies.
Tumour Samples Concentration (ng/ul) RNA integrity
1
1 129.6 9.7
2 17.2 -
2
3 63.2 9.3
4 too low/undetectable -
3
5 326 9.3
6 208 9.3
4
7 118 9.3
8 76 9
5
9 208 10
10 142 9.8
6
11 115.6 9.9
12 29.2 8.5
7
13 272 10
14 56 10
Tumour Samples Concentration (ng/ul) RNA integrity
8
15 182.8 9.6
16 169.2 9.6
9
17 147.4 9.5
18 16.6 -
10
19 99.6 9.4
20 105.6 9.3
11
21 98 9.5
22 12.6 -
12
23 41.4 9.1
24 82.8 9.7
13
25 282 10
26 228 9.9
14
27 308 9.9
28 304 10
15
29 258 10
30 370 10
16
31 800 10
32 1120 10
17
33 197.8 9.7
34 244 9.6
18
35 286 9.6
36 148 9.5
19
37 234 9.4
38 250 9.6
20
39 362 9.7
40 254 9.6
21
41 252 10
42 55 10
22
43 49.6 9.8
44 26 9.5
23
45 17.2 9.2
46 21 9.8
24
47 25 8.6
48 too low/undetectable -
25
49 360.8 9.7
50 194.8 9.6
26
51 110.6 9.3
52 50.6 9
27
53 15.8 8.7
54 16.6 9
28
55 26.6 8.8
56 too low/undetectable -
Average: 180.8 9.5
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Table 2. RNA concentrations and 
integrity of 10 normal skin samples 
studied. Qualitative and quantitative 
measurements of the total RNA isolated 
from normal skin punch biopsies.
Samples Concentration (ng/ul)
RNA 
Integrity
1 25.2 9.6
2 17 8.8
3 18.6 9.2
4 23 10
5 38.6 9.5
6 20.2 9.5
7 32 9.4
8 36.6 9.4
9 40 9.8
10 21.8 9.7
Average: 27.3 9.5
Table 3. Expression of known cytokeratin signatures of differentially expressed genes in 
cylindroma and spiradenoma compared to control skin.
Gene log2 Fold Change Prob. FDR Description
KRT13 3.94 1.37E-11 Keratin 13
KRT17P2 2.44 0.011702576 Keratin 17 pseudogene 2
KRTCAP3 1.05 0.012251062 Keratinocyte associated protein 3
TCHP -0.83 0.022666568 Trichoplein keratin filament binding
KRT15 -0.89 0.031124672 Keratin 15
KRT3 -1.56 0.016500418 Keratin 3
KRT9 -1.71 0.002468716 Keratin 9
KRT5 -1.74 0.000610354 Keratin 5
KRT8P26 -1.96 0.012588263 Keratin 8 pseudogene 26
KRT80 -1.96 0.017781638 Keratin 80
KRT19 -2.07 0.035571416 Keratin 19
KPRP -2.20 0.013678232 Keratinocyte proline rich protein
KRTDAP -2.35 0.001196344 Keratinocyte differentiation associated protein
KRT78 -2.39 0.00676354 Keratin 78
KRT10 -2.46 0.00126146 Keratin 10
KRT14 -2.48 0.00000538 Keratin 14
KRT1 -2.55 0.000588345 Keratin 1
KRT77 -2.67 0.00000744 Keratin 77
KRT72 -2.71 0.000336864 Keratin 72
KRT27 -2.76 0.005439881 Keratin 27
KRT73 -3.37 3.44E-08 Keratin 73
KRT31 -3.89 4.65E-11 Keratin 31
KRT2 -4.02 0.000000475 Keratin 2
Page 6 of 12
Wellcome Open Research 2018, 3:45 Last updated: 01 JUN 2018
RNA sequencing validates tumour transcriptomic signature
Reads derived from next generation sequencing were sub-
ject to quality control using FASTQc (Figure 1d), and this 
demonstrated high quality scores, consistent with the high 
integrity RNA used. Differential gene expression studies 
focussed on known differentially expressed signature cytokera-
tin genes in cylindroma and spiradenoma, skin tumours seen in 
CYLD cutaneous syndrome (Brown et al., 2018). This con-
firmed that the recognised cytokeratin signature was expressed 
in these tumour transcriptomes (Table 3).
Discussion
Due to its high sensitivity and resolution, RNA sequencing is 
a powerful tool for investigation of skin disease. It can pro-
vide mechanistic insights behind disease pathogenesis, which 
may offer prognostic information, prediction of response to 
treatments and the potential for developing novel therapies 
(Gilmore, 2013). To overcome the inherent difficulties of 
obtaining high integrity RNA, there are in general, four 
crucial steps required during extraction: cells or tissues should 
be completely homogenised; nucleoprotein complexes should be 
disrupted; RNase should be inactivated; contamination includ-
ing carbohydrate, lipids, protein and other nucleic acid 
should be avoided (Buckingham & Flaws, 2007; Doyle & 
Doyle, 1990).
We describe a novel method, incorporating cryostat section-
ing, resulting in partial disruption of the tissue, whilst simul-
taneously allowing us to take 8 μm sections for histological 
assessment. We used bead-based tubes that allowed for up to 
24 samples to be processed simultaneously. Importantly, we were 
able to work with small amounts of skin, which were robustly 
disrupted using the bead-based lysis system we employed. 
This prevented carryover of incompletely homogenised mate-
rial and obstruction of spin columns used for RNA extrac-
tion. The bead-based lysis system we employed had a range of 
disruption settings and after optimisation with a range of bead 
sizes, we chose a medium bead mix (CK28 Mix), and lysis of 
20 seconds at 5500 rpm in lysis buffer as this gave optimal RNA 
extraction and RINs.
After skin homogenisation, there are several established meth-
ods for RNA extraction. Phenol/chloroform extraction, one of 
the commonly used techniques, has potential for phenol contami-
nation of the samples, which is often reported (Oñate-Sánchez 
& Vicente-Carbajosa, 2008). Therefore, we employed a silica 
column-based RNA extraction methodology (Sellin Jeffries 
et al., 2014). This approach suited our protocol, which required 
small volumes of lysis buffer, and elution of RNA performed 
in 14ul of water. This typically resulted in highly concentrated 
samples and thus satisfied the requirements of most RNA 
library preparation kits for next generation sequencing.
Given RNA’s sensitivity to temperature, we developed a protocol 
where the skin sample is kept as cold as possible throughout. 
The tumour samples were first snap frozen in liquid nitrogen, 
and then cryosectioned at a temperature of -20°C. During rapid 
homogenisation in our protocol, the tumour material was exposed 
to ambient temperatures for only a few minutes. This was imme-
diately followed by RNA extraction in a precooled centri-
fuge at 4°C. Spin columns were incubated on wet ice between 
centrifugation steps and eluted RNA was immediately frozen 
after RNA extraction was complete.
In summary, we developed a method for efficient extraction 
of RNA from small cryosectioned pieces of human skin with 
histological data from adjacent tissue sections. We validated this 
method in human skin tumours samples in a clinical trial setting. 
This protocol could be utilised in healthy and diseased skin to 
improve mechanistic understanding in a range of human skin 
disease and cancer.
Data availability
FASTQ files (controls [n=3] and tumours [n=3] used to 
generate validation signatures), sample description files and 
uncropped gel images are available at Open Science Framework: 
http://doi.org/10.17605/OSF.IO/5YX96 (Rajan, 2018).
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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The paper "Transcriptomic profiling of human skin biopsies in the clinical trial setting: A protocol for high
quality RNA extraction from skin tumours" talks about a novel method to isolate high quality RNA from
skin biopsies in a clinical trial setting.
The method is well described and provides information on several aspects to consider in the course of
respective sample preparation.
However, we would like to address some points we noticed:
Authors state that this is a new method, circumventing several critical aspects of RNA extraction.
However, we feel that the novelty is not well enough discussed. A comparison of the key aspects
with some aspects of other standard procedures would facilitate a better understanding of the
advantages. Optimally, simultaneous RNA preparation with a commonly used method would have
been interesting as a methodical control.
 
 The problem statement should be elaborated more in detail in the introduction.
 
A statement on why these skin tumours were chosen for the establishment of the method should
be included and how patients could benefit from this method in the clinical trial setting.
 
Minor points:
Some more information on the gene expression signature should be given in the text and what
relevance the validation of the expression profile has in a clinical trial setting.
 
Table 3: A short statement on the results shown in the table would be helpful in the table
description.
 
Figure 1D is not comprehensively described.
 
Why is the final average RNA concentration 10-fold higher in tumour samples compared to normal
1 2
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Why is the final average RNA concentration 10-fold higher in tumour samples compared to normal
skin biopsies? (Tables 1 and 2)
 
Table 1. Subtitle: … is “normal” skin biopsies correct?
 
Some typos / spaces in the paper. (eg. abstract paragraph 2: c ostat; page 5:    false discoveryYR A
rate , …)S
Is the rationale for developing the new method (or application) clearly explained?
Partly
Is the description of the method technically sound?
Yes
Are sufficient details provided to allow replication of the method development and its use by
others?
Yes
If any results are presented, are all the source data underlying the results available to ensure full
reproducibility?
Yes
Are the conclusions about the method and its performance adequately supported by the
findings presented in the article?
Yes
 No competing interests were disclosed.Competing Interests:
We have read this submission. We believe that we have an appropriate level of expertise to
confirm that it is of an acceptable scientific standard.
 24 May 2018Referee Report
doi:10.21956/wellcomeopenres.15623.r33121
 Irene M. Leigh
Centre for Cutaneous Research, Barts and the London School of Medicine and Dentistry, Queen Mary
University of London, London, UK
The results show very good RIN figures by careful attention to detail to inhibit skin RNAases and prevent
degradation of RNA etc. The transcriptomic profiling of skin disease for research purposes is well
established and it would improve the article to have clarity about the innovative features of this
methodology compared to other published studies. The preparation of normal skin has also resulted in
very good RIN here but there could be more detail about this. Has the biopsy been treated whole/ fat
removed etc? Were the 10 30-micron curls used for normal skin also. Laser capture (discussed) is
probably not a competitor for this in skin as heating results in lower RNA integrity. Cylindroma and
trichoepithlioma are very cellular tumours not hyperkeratotic lesions: would this work in much commoner
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trichoepithlioma are very cellular tumours not hyperkeratotic lesions: would this work in much commoner
keratotic tumours? Such a method is of course mainly suitable for research studies and clinical trials not
for routine pathology labs where transcriptomic profiling is needed on FFPE sections.
Is the rationale for developing the new method (or application) clearly explained?
Yes
Is the description of the method technically sound?
Yes
Are sufficient details provided to allow replication of the method development and its use by
others?
Yes
If any results are presented, are all the source data underlying the results available to ensure full
reproducibility?
Yes
Are the conclusions about the method and its performance adequately supported by the
findings presented in the article?
Yes
 No competing interests were disclosed.Competing Interests:
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 24 April 2018Referee Report
doi:10.21956/wellcomeopenres.15623.r32972
   Veronica A. Kinsler
 Pediatric Dermatology, Great Ormond Street Hospital for Children, London, UK
 Genetics and Genomic Medicine, UCL Institute of Child Health, London, UK
Overall this is an excellent contribution to technical knowledge of handling of skin samples, and a
well-presented methods paper in so far as the optimised extraction method goes.
I have a few points to be addressed:
You are not comparing extraction techniques here, but sample preparation. In this context, there is
inadequate information on the handling of the "control" skin samples - detail is needed on how
these were taken, how long they were left (and in what?) before extraction. If an RNA stabilisation
solution was not used as a comparator this should be addressed, as really this would be the
current gold standard for comparison, not direct extraction from a tissue sample that had been left
in the fridge or in culture medium. In addition it is not clear whether the normal skin biopsies were
also 4-6mm, or whether these were all 4mm.
 
It is possible to divide even a 4mm skin biopsy for histology and RNA extraction and still get
1,2
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It is possible to divide even a 4mm skin biopsy for histology and RNA extraction and still get
enough for a library prep, so the claim that this method is the only one which would allow histology
is not correct
 
It is possible that tumours and normal skin differ intrinsically in the amount of RNA produced, and
that this is responsible for the differences in quantity, particularly as the quality of the RNA is the
same from tumour and normal skin. It would have been much better to use half of each tumour
biopsy for each preparation method, and if this could be done on 10 samples going forward you
would have a much stronger paper. If not possible in the clinical context this point at least needs to
be addressed specifically in the discussion.
Is the rationale for developing the new method (or application) clearly explained?
Yes
Is the description of the method technically sound?
Partly
Are sufficient details provided to allow replication of the method development and its use by
others?
Yes
If any results are presented, are all the source data underlying the results available to ensure full
reproducibility?
Yes
Are the conclusions about the method and its performance adequately supported by the
findings presented in the article?
Yes
 No competing interests were disclosed.Competing Interests:
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
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